Scholarlink

<p>The programmed cell death protein 1 (PD‑1)/programmed death‑ligand 1 (PD‑L1) signaling axis is recognized as a central pathway maintaining immune suppression. Within the liver’s inherently tolerogenic microenvironment, parenchymal, non‑parenchymal and immune cell populations are engaged in a dynamic regulatory network mediated by PD‑1/PD‑L1, which serves to preserve immune homeostasis and to balance innate and adaptive immune responses. Aberrant PD‑1/PD‑L1 signaling has been implicated across the disease continuum of many chronic liver disorders, spanning viral hepatitis, fibrosis, and hepatic malignancy. A systematic synthesis is presented of the regulatory roles and recent advances concerning the PD‑1/PD‑L1 axis in viral hepatitis, metabolic dysfunction‑associated fatty liver disease (MAFLD), autoimmune liver diseases and related conditions. Mechanisms regulating PD‑1/PD‑L1 expression and function in hepatocellular carcinoma (HCC) are comprehensively summarized, including tumor microenvironmental determinants, intracellular signaling cascades, post‑translational modifications and epigenetic control. A theoretical framework and novel perspectives are thereby provided for elucidating PD‑1/PD‑L1 dysregulation in chronic liver disease, for identifying candidate biomarkers, and for informing the development of precision immunotherapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of PD‑1/PD‑L1 axis in liver diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月12日

查看全文
  • Zijian Zeng,
  • Shuanglan Chen,
  • Qun Niu,
  • Haijian Dong,
  • Yuanqian Yao,
  • Kaixin Wang,
  • Xueqing Gong,
  • Hui Li

摘要

The programmed cell death protein 1 (PD‑1)/programmed death‑ligand 1 (PD‑L1) signaling axis is recognized as a central pathway maintaining immune suppression. Within the liver’s inherently tolerogenic microenvironment, parenchymal, non‑parenchymal and immune cell populations are engaged in a dynamic regulatory network mediated by PD‑1/PD‑L1, which serves to preserve immune homeostasis and to balance innate and adaptive immune responses. Aberrant PD‑1/PD‑L1 signaling has been implicated across the disease continuum of many chronic liver disorders, spanning viral hepatitis, fibrosis, and hepatic malignancy. A systematic synthesis is presented of the regulatory roles and recent advances concerning the PD‑1/PD‑L1 axis in viral hepatitis, metabolic dysfunction‑associated fatty liver disease (MAFLD), autoimmune liver diseases and related conditions. Mechanisms regulating PD‑1/PD‑L1 expression and function in hepatocellular carcinoma (HCC) are comprehensively summarized, including tumor microenvironmental determinants, intracellular signaling cascades, post‑translational modifications and epigenetic control. A theoretical framework and novel perspectives are thereby provided for elucidating PD‑1/PD‑L1 dysregulation in chronic liver disease, for identifying candidate biomarkers, and for informing the development of precision immunotherapeutic strategies.